XLO vs. IMRX, ENTA, SPRO, LXEO, THTX, GLSI, RAPT, IKT, MOLN, and LYEL
Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Immuneering (IMRX), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), Greenwich LifeSciences (GLSI), Rapt Therapeutics (RAPT), Inhibikase Therapeutics (IKT), Molecular Partners (MOLN), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry.
Xilio Therapeutics vs. Its Competitors
Xilio Therapeutics (NASDAQ:XLO) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.
Xilio Therapeutics has a beta of -0.15, meaning that its share price is 115% less volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.
Immuneering has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -585.54%. Immuneering's return on equity of -119.22% beat Xilio Therapeutics' return on equity.
In the previous week, Immuneering had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Immuneering and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.89 beat Immuneering's score of 0.81 indicating that Xilio Therapeutics is being referred to more favorably in the media.
54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by company insiders. Comparatively, 22.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Xilio Therapeutics has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Xilio Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 447.65%. Immuneering has a consensus target price of $13.25, indicating a potential upside of 234.60%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Xilio Therapeutics is more favorable than Immuneering.
Summary
Xilio Therapeutics and Immuneering tied by winning 8 of the 16 factors compared between the two stocks.
Get Xilio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xilio Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:XLO) was last updated on 7/17/2025 by MarketBeat.com Staff
Free XLO Stock Alerts